Durham, N.C. (PRWEB) July 22, 2012
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the launch of the new Smasher™ XL large capacity blender and homogenizer. The Smasher XL prepares samples up to 375g and can process one four-liter bag or two two-liter bags simultaneously. It combines the capability to efficiently process large volumes up to four liters with short blending times to help improve lab productivity. The new Smasher XL will be featured at the International Association for Food Protection (IAFP) Annual Meeting in Providence, Rhode Island (July 22-25) at bioMérieux booth #619.
The Smasher XL’s patented “SMASH” effect avoids jams and streamlines laboratory workflow by eliminating the need to continuously reposition the sample bag during sample preparation. The Smasher XL’s four paddles provide a perfectly homogenized suspension required to help ensure reproducible test results. It senses if a sample is preventing full travel of its paddles and automatically returns to the starting position to resume homogenization.
“Food laboratories today are striving to improve productivity and shorten their time-to-results, and the Smasher XL becomes a highly relevant tool to help achieve those goals,” said Jeff Papi, Sr. Marketing Manager for Lab Automation at bioMérieux Industry. “Its ability to blend large samples quickly and produce fully homogenized samples is a great new development for food microbiology laboratories.”
The Smasher XL is also designed for easy maintenance. It features an integrated waste drawer, and the door and paddles can be quickly removed without tools to improve ease-of-use and reduce service requirements.
Finally, the Smasher XL was designed with safety and ergonomics in mind. The paddles stop immediately once the door is opened for maximum safety, and realign for easy loading and unloading of sample bags.
For more information on Smasher XL and other bioMérieux Industry technologies, please visit http://www.biomerieux-usa.com/LabAuto.
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 40 subsidiaries and a large network of distributors. In 2011, revenues reached €1.427 billion with 87% of sales outside of France.
bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).